drugset / Trial / NCT00327990

Evaluation Of Missed Osteoporosis Diagnoses, And Preference Between Once Monthly Ibandronate And Once Weekly Alendronate

NCT00327990

Phase 4 Completed 300 enrolled GlaxoSmithKline
RandomizedCrossoverOpen-labelTreatment

Summary

This is a two part study (screening and treatment). The first part (screening) is designed to evaluate the percentage of patients missed in diagnosing osteoporosis by general practitioners (GP's). The second part (treatment) is designed to determine the preference by patients for the once monthly ibandronate or the once weekly alendronate.

Timeline

Start
2005-04
Primary completion
2006-12
Completion
2006-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Alendronic Acid Small molecule 70 mg
Subject Ibandronate Other / unclassified 150 mg

Indications